EMEric Mirallié

Eric Mirallié

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric Mirallié has a total of 312 co-authors. Here are the top co-authors by number of shared publications:

  • Cécile Caillard

    CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, Nantes Université, France

    13 shared publications
  • Antoine Hamy

    CHU Angers, Chirurgie Digestive et Endocrinienne, Angers Cedex 09, France

    10 shared publications
  • Claire Blanchard

    Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l’Appareil Digestif, Nantes, France

    10 shared publications
  • Laurent Brunaud

    Département de chirurgie viscérale, métabolique et cancérologique, Inserm N-GERE, CHRU de Nancy, université de Lorraine, 54000 Nancy, France

    10 shared publications
  • Samuel Frey

    CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, Nantes Université, France; CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes Université, France

    10 shared publications
  • Claire Blanchard

    Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, CHU de Nantes, France; Université de Nantes, France; Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France

    9 shared publications

Latest Publications

  • Parathyroid near-infrared autofluorescence use for parathyroidectomy in mild primary hyperparathyroidism: Results from a randomized monocentric trial

    by Samuel Frey, Sahar Bannani, Cécile Caillard, Maëlle Le Bras, Delphine Drui, Catherine Ansquer, Pascale Guillot, Aurélie Le Thuaut, Eric Mirallié


  • Amiodarone-induced thyrotoxicosis: Should surgery be considered?

    by Samuel Frey, Cécile Caillard, Pascale Mahot, Delphine Drui, Eric Mirallié


  • Parathyroidectomy Improves Bone Density in Women With Primary Hyperparathyroidism and Preoperative Osteopenia

    by Samuel Frey, Maxime Gérard, Pascale Guillot, Matthieu Wargny, Kalyane Bach-Ngohou, Edith Bigot-Corbel, Nelly Renaud Moreau, Cécile Caillard, Eric Mirallié, Bertrand Cariou, et al.

    Context Osteoporosis and/or bone fractures are indications of parathyroidectomy in primary hyperparathyroidism (PHPT), especially in women. However, the benefit of surgery in patients with osteopenia remains unclear. Objective To evaluate bone mineral density (BMD) and bone remodeling biomarkers changes 1 year after parathyroidectomy in women with PHPT. Design In the prospective, monocentric, observational prospective cohort with primary hyperparathyroidism patients (CoHPT) cohort, women operated for sporadic PHPT since 2016 with ≥1 year follow-up were included. BMD (dual-X ray absorptiometry) and bone remodeling biomarkers [cross-linked C-telopeptide (CTX), procollagen type 1 N-terminal propeptide (P1NP), and bone-specific alkaline phosphatases] were assessed before and 1 year after parathyroidectomy. Setting Referral center. Patients A total of 177 women with PHPT (62.5 ± 13.3 years, 83.1% menopausal, 43.9% osteopenic, and 45.1% osteoporotic) were included. Intervention Parathyroidectomy. Main Outcome Measure BMD change between before and 1 year after parathyroidectomy. Results Parathyroidectomy resulted in significant increase in BMD and decrease in serum bone remodeling biomarker concentrations. In the 72 patients with baseline osteopenia, mean BMD significantly increased at the lumbar spine [+0.05 g/cm2 (95% confidence interval [CI], 0.03–0.07)], the femoral neck [+0.02 g/cm2 (95% CI 0.00–0.04)], the total hip [+0.02 g/cm2 (95% CI 0.01–0.02)], and the forearm [+0.01 (95% CI 0.00–0.02)], comparable to osteoporotic patients. Among osteopenic patients, those with individual BMD gain (>0.03 g/cm2) at ≥1 site had higher preoperative serum CTX, P1NP, and urine calcium concentrations than those without improvement. Conclusion Parathyroidectomy significantly improved BMD and remodeling biomarkers in women with osteopenia, thereby supporting the benefit of parathyroidectomy in these patients. Preoperative serum CTX and P1NP concentrations could be useful to predict expected BMD gain.


  • Do men improve their bone mineral density 1 year after parathyroidectomy for primary hyperparathyroidism? Results of a prospective study

    by Samuel Frey, Pascale Guillot, Matthieu Wargny, Maxime Gérard, Edith Bigot-Corbel, Kalyane Bach-Ngohou, Cécile Caillard, Bertrand Cariou, Eric Mirallié, Claire Blanchard


  • Open Access

    Surgery for Primary Aldosteronism in France From 2010 to 2020 – Results from the French-Speaking Association of Endocrine Surgery (AFCE)

    by Timothée Vignaud, Grégory Baud, Claire Nominé-Criqui, Gianluca Donatini, Nicolas Santucci, Antoine Hamy, Jean-Christophe Lifante, Laure Maillard, Muriel Mathonnet, Nathalie Chereau, et al.

    Objective: Describe the diagnostic workup and postoperative results for patients treated by adrenalectomy for primary aldosteronism in France from 2010 to 2020 Background: Primary aldosteronism (PA) is the underlying cause of hypertension in 6% to 18% of patients. French and international guidelines recommend CT-scan and adrenal vein sampling as part of diagnostic workup to distinguish unilateral PA amenable to surgical treatment from bilateral PA that will require lifelong antialdosterone treatment. Adrenalectomy for unilateral primary aldosteronism has been associated with complete resolution of hypertension (no antihypertensive drugs and normal ambulatory blood pressure) in about one-third of patients and complete biological success in 94% of patients. These results are mainly based on retrospective studies with short follow-up and aggregated patients from various international high-volume centers. Methods: Here we report results from the French-Speaking Association of Endocrine Surgery (AFCE) using the Eurocrine® Database. Results: Over 11 years, 385 patients from 10 medical centers were eligible for analysis, accounting for >40% of adrenalectomies performed in France for primary aldosteronism over the period. Preoperative workup was consistent with guidelines for 40% of patients. Complete clinical success (CCS) at the last follow-up was achieved in 32% of patients, and complete biological success was not sufficiently assessed. For patients with 2 follow-up visits, clinical results were not persistent at 1 year for one-fifth of patients. Factors associated with CCS on multivariate analysis were body mass index, duration of hypertension, and number of antihypertensive drugs. Conclusions: These results call for an improvement in thorough preoperative workup and long-term follow-up of patients (clinical and biological) to early manage hypertension and/or PA relapse.


  • Open Access

    Parathyroidectomy for primary hyperparathyroidism: effect on quality of life after 3 years – a prospective cohort study

    by Samuel Frey, Bastien Msc Perrot, Cécile Caillard, Maëlle Le Bras, Maxime Gérard, Claire Blanchard, Bertrand Cariou, Matthieu Wargny, Eric Mirallié

    Background: The impact of parathyroidectomy (PTX) for primary hyperparathyroidism (PHPT) on long-term quality of life (QoL) remains controversial. The study evaluated QoL changes 1 and 3 years after PTX. Materials and Methods: Patients undergoing PTX for PHPT between 2016 and 2022 (n=329) were enrolled in this monocentric, prospective cohort study. QoL was evaluated using the SF-36 questionnaire before, 1 year, and 3 years after PTX and compared with an age-matched and sex-matched French reference population. Only patients with 1-year and 3-year follow-up and complete evaluation (serum calcium, phosphorus, parathyroid hormone) were included. Results: A total of 159 patients were included (mean age: 62.6±12.7 years, 79.2% females). Mean serum calcium (2.66±0.20 mmol/l) and median parathyroid hormone (96.4 [76.9−126.4] pg/ml) levels improved significantly after PTX. Before surgery, PHPT patients had impaired physical (44.6±8.9 vs. 47.6±6.8 in the reference population, PPP<0.01). The mean mental component score increased significantly at 1 and 3 years, but remained significantly lower than the reference population. Before surgery, a lower physical component score and younger age were significantly associated with a 3-year physical component score increase on multiple linear regression analysis. Conclusion: A significant improvement in QoL is associated with PTX for PHPT at 1 year and is sustained for at least 3 years after surgery.


  • Open Access

    Prospective Multicentric Assessment of 68Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET

    by Alexandre Lugat, Éric Frampas, Yann Touchefeu, Éric Mirallié, Maëlle Le Bras, Hélène Senellart, Aurore Rauscher, Vincent Fleury, Loïc Campion, Vincent Rohmer, et al.

    The aim of this multicentric study was to prospectively compare 68Ga-DOTANOC PET/CT versus somatostatin receptor scintigraphy (SRS) with SPECT/CT, combined with multiphasic CT scan and MRI in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET). Patients with histologically proven grade 1 or 2 GEP-NET with suspicion of recurrence or progression, or with typical aspects of GEP-NET on morphological imaging, were explored with conventional imaging (CI): SRS with SPECT/CT, multiphasic CT scan and/or liver MRI followed by 68Ga-DOTANOC PET/CT. The gold standard was based on histology and imaging follow-up. The data of 105 patients (45 woman and 60 men; median age) were analyzed. 68Ga-DOTANOC PET/CT sensitivity was significantly higher than CI sensitivity in per-patient (98.9% vs. 88.6%, p = 0.016) and per-region (97.6% vs. 75.6%, p < 0.001) analyses, in the detection of the primary (97.9% vs. 78.7%; p = 0.016), peritoneal carcinomatosis (95% vs. 30%, p < 0.001), and bone metastases (100% vs. 33.3%, p = 0.041). 68Ga-DOTANOC PET/CT had an impact on the therapeutic management of 41.9% (44/105) patients compared to decisions based on CI explorations. Our data confirm the superiority of 68Ga-DOTANOC PET/CT over CI in the detection of peritoneal carcinomatosis and bone metastasis, as well as its strong therapeutic impact on the management of patients with grade 1-2 GEP-NETs.


  • Prise en charge chirurgicale de l’hyperthyroidie à l’amiodarone : expérience nantaise entre 2010 et 2020

    by C. Caillard, S. Frey, P. Mahot, S. Pattier, G. Lande, E. Mirallié, D. Drui

  • Effects of parathyroidectomy on kidney function in patients with primary hyperparathyroidism: Results of a prospective study

    by Samuel Frey, Matthieu Wargny, Claire Blanchard, Cécile Caillard, Samy Hadjadj, Bertrand Cariou, Lucile Figueres, Eric Mirallié


  • Life expectancy and likelihood of surgery in multiple endocrine neoplasia type 1: AFCE and GTE cohort study

    by Sébastien Gaujoux, Guillaume L Martin, Eric Mirallié, Nicolas Regenet, Maëlle Le Bras, François Pattou, Bruno Carnaille, Catherine Cardot-Bauters, Lionel Groussin, Matthieu Faron, et al.

    The overall natural history, risk of death and surgical burden of patients with multiple endocrine neoplasia type 1 (MEN1) is not well known. Patients with MEN1 from a nationwide cohort were included. The survival of patients with MEN1 was compared with that of the general population using simulated controls. The cumulative probabilities of MEN1-specific operations and postoperative mortality were assessed, and surgical sequences were analysed using sunburst charts and Venn diagrams. A total of 1386 patients with MEN1 were included. Life expectancy was significantly reduced in patients with MEN1 compared with simulated controls from the general population, with a lifetime difference of 15 years. Mutations affecting the JunD interaction domain had a significant negative impact on survival. Survival for patients with MEN1 compared with the general population improved over time. The probability of experiencing at least one specific MEN1 operation was above 95 per cent after 75 years, and most patients had surgery at least twice during their lifetime. Time to a 50 per cent risk of MEN1 surgery was 30.5 years for patients born after 1960, compared with 47.9 years for those born before 1960. Sex and mutations affecting the JunD interacting domain had no impact on time to first surgery. There was considerable heterogeneity in surgical sequences, with no specific clinical pathway. Life expectancy was significantly lower among patients with MEN1 compared with the general population, and further decreased in patients with mutations affecting the JunD interacting domain. Almost all patients underwent at least one MEN1-specific operation during their lifetime, but there was no standardized sequence of surgery.